Davita Takes Control of Ecuadorian Dialysis Provider Cendialcon

Ecuador's Superintendence of Economic Competition authorized Davita Cía. Ltda. to acquire 100% of the shares of Centro de Diálisis Contigo Cendialcon Cía. Ltda., an Ecuadorian dialysis provider, according to Primicias.

The decision was issued on August 17, 2026. The regulator reviewed the transaction in the private-complementary hemodialysis markets of Latacunga and Ambato and concluded that the purchase did not materially change the competitive structure of those markets or create immediate horizontal anticompetitive risks.

The scale behind the deal

Primicias describes Davita as a U.S. multinational specializing in renal-care services. The group already has a network of 29 establishments in Ecuador, and the competition authority said that continued national expansion should be monitored in future transactions.

The healthcare context is significant. Around 20,000 people in Ecuador need dialysis or hemodialysis to survive. The treatment has been covered by the state since 2008 because it is classified as a catastrophic illness, but the public system does not have enough capacity to serve everyone. The report says 88%, or about 17,000 people, are referred to private clinics.

Each patient receives three four-hour sessions per week, according to the report.

Cendialcon’s financial pressure

Cendialcon closed 2025 with 261 patients, up 11.5% from the previous year. Its accounts receivable reached USD 5.71 million, an increase of 27.13% from 2024, while the average collection time reached 486 days. Primicias attributes the receivables pressure mainly to pending payments from the Ministry of Public Health and IESS.

Those figures place the acquisition in a wider operating context: patient demand, public payment cycles, and private-provider capacity are linked.

What this means for expats

The approval does not itself announce a change to patient contracts, prices, clinic locations, or access rules for foreign residents. The relevant point is system capacity. Expats who rely on private healthcare should watch the operating details of clinics they use, while businesses and analysts should watch how consolidation interacts with public reimbursements and provider liquidity.

The source does not publish the purchase price or a post-close operating plan. For now, the verified event is a regulator-approved acquisition inside a dialysis market that serves a large patient population and depends heavily on private facilities.

Source: Primicias

The transaction is a useful example of how Ecuador's private healthcare markets can depend on public-sector payment cycles. The competition authority focused on the private-complementary hemodialysis markets in Latacunga and Ambato, while the financial figures reported for Cendialcon show why liquidity is a central operating issue for providers serving publicly referred patients.

The patient numbers show the scale of the service. Around 20,000 people in Ecuador need dialysis or hemodialysis to survive. Because the condition is classified as a catastrophic illness, the state has covered the treatment since 2008. Yet the public system does not have sufficient capacity for everyone, and 88%, or about 17,000 people, are referred to private clinics.

That arrangement creates a recurring operational dependency. Each patient receives three four-hour sessions per week, according to the report. A clinic therefore needs dependable staffing, equipment, and cash flow at the same time. When public reimbursements are delayed, the provider can continue delivering treatment while the receivable grows on its books.

The figures for Cendialcon illustrate that pressure without revealing the purchase price. The company ended 2025 with 261 patients, an 11.5% increase from the prior year. Its accounts receivable reached USD 5.71 million, up 27.13% from 2024, and average collection time reached 486 days. Primicias attributes the receivables pressure mainly to pending payments from the Ministry of Public Health and IESS.

For patients and families, the immediate question is continuity at the clinics involved, not a change announced by the authorization itself. The source does not publish a new pricing schedule, patient-contract change, clinic relocation, or post-close operating plan. For businesses and investors, the more concrete watchpoints are future consolidation decisions, reimbursement timing, and whether the enlarged provider network changes capacity in the markets covered by the regulator.